ARTICLE | Product Development
Editas drops NK cells as efficacy questions persist for modality
Editas halts investment in NK cell and retinal disease programs; starts search for CSO with in vivo therapy expertise
January 9, 2023 8:00 PM UTC
Updated on Jan 9, 2023 at 10:34 PM UTC
NK cell therapies may still have an efficacy problem, and Editas’ retreat from iPSC-derived NK cells is the second sign in less than a week that some biotechs are losing confidence in the modality amid the rising success of T cell therapies.
In advance of its presentation at the J.P. Morgan Healthcare Conference, Editas Medicine Inc. (NASDAQ:EDIT) announced a pipeline reorganization that includes dropping its preclinical NK cell therapy programs including EDIT-202 to focus on its stem cell and T cell therapies. ...